Table 5.
Multivariate Cox hazard analysis of factors associated with overall survival after the first- and second-line chemotherapies
| Factors | First-line chemotherapy
|
Second-line chemotherapy
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| ECOG PS | ||||||
| 0–1 vs 2–4 | 3.34 | 2.00–5.58 | <0.01 | – | – | – |
| Stage | ||||||
| I–III vs IV | 1.40 | 0.86–2.28 | 0.18 | – | – | – |
| Platelet-to-lymphocyte ratio | ||||||
| <150 vs ≥150 | 1.44 | 0.87–2.39 | 0.16 | 0.96 | 0.52–1.78 | 0.90 |
| Hemoglobin (g/dL) | ||||||
| ≥11 vs <11 | 1.43 | 0.72–2.82 | 0.31 | – | – | – |
| Serum sodium (mE q/L) | ||||||
| ≥135 vs <135 | 1.40 | 0.79–2.48 | 0.24 | 0.86 | 0.37–2.01 | 0.73 |
| LDH (IU/L) | ||||||
| <225 vs ≥225 | 1.63 | 0.99–2.68 | 0.052 | 1.62 | 0.89–2.94 | 0.12 |
| CRP (mg/dL) | ||||||
| <1 vs ≥1 | 1.47 | 0.85–2.55 | 0.17 | 2.67 | 1.30–5.47 | <0.01 |
| PFS after the first-line chemotherapy (months) | ||||||
| ≥6 vs <6 | – | – | – | 2.85 | 1.50–5.43 | <0.01 |
Notes: Coded as 1 (ECOG PS 2–4, stage IV, platelet-to-lymphocyte ratio ≥150, hemoglobin <11 g/dL, serum sodium <135 mEq/L, LDH ≥225 IU/L, CRP ≥1 mg/dL, and PFS after the first-line chemotherapy <6 months) and as 0 (ECOG PS 0–1, stages I–III, platelet-to-lymphocyte ratio <150, hemoglobin ≥11 g/dL, serum sodium ≥135 mEq/L, LDH <225 IU/L, CRP <1 mg/dL, and PFS after the first-line chemotherapy ≥6 months).
Abbreviations: CI, confidence interval; CRP, C-reactive protein; ECOG, European Clinical Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; PFS, progression-free survival; PS, performance status.